retatrutide triple agonist glp-1 gip glucagon phase 2 obesity LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept When the Breakthrough Obesity G-Agonist

Month 4 (1.5mg): Therapeutic range $447

Our Weightless Patches support weight management with Berberine, Pomegranate, and Cinnamon Extracts to balance blood sugar and curb cravings

Skin tightening works on the face, neck, and cellulite on the stomach, thighs, and buttockstwo powerful additions to GLP-1s that will tone and sculpt as you reach your ideal weight

I encourage accurate food journaling to avoid unintentional calorie creep. 2

Clinical trials have demonstrated varying efficacy across the class, with weight reductions ranging from approximately 5-8% with liraglutide 3 mg to 15% with semaglutide 2.4 mg and 10-22% with tirzepatide, depending on dose